Deals and Data

Deals and Data

Eli Lilly and Co’s Cyramza stomach cancer drug prolongs survival of patients with advanced colon cancer in late-stage study. (Reuters, 09/12/14)

Boehringer Ingelheim and Eli Lilly’s basal insulin Abasria gets green light; offers patients with diabetes a new option for long-lasting sugar control. (PharmaTimes Digital, 09/10/14)

FDA approves Astellas Pharma and Medivation Inc’s advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy. (Reuters, 09/10/14)

FDA approves Sanofi’s Menactra for booster vaccination against meningococcal disease caused by Neisseria meningitides serogroups A, C, Y, and W-135. (Medscape, 09/11/14)

Novo Nordisk’s diabetes drug, liraglutide, approved for treating obesity; spurs pancreas to create extra insulin after meals. (, 09/11/14)

FDA approves Halozyme Therapeutics and Baxter International’s Hyqvia for the treatment of adults with primary immunodeficiency. (PharmaTimes Digital, 09/14/14)

Salk Institute upends belief on how the body gets rid of dead cells; may guide research into treating autoimmune diseases, cancer, and an inherited eye disease that causes blindness. (U-T San Diego, 09/15/14)

Merck seeks approval of osteoporosis drug, odanacatib; significantly reduces risk of fractures of the hip and spine. (Reuters, 09/15/14)

Shire’s hyperactivity drug Vyvanse gets priority review as potential treatment for binge eating disorder. (Reuters, 05/15/14)

FDA approves AstraZeneca and Nektar Therapeutics’ oral therapy to treat opioid-induced constipation. (Reuters, 09/16/14)

Eli Lilly and AstraZeneca to jointly develop and commercialize high-risk, Phase II/III-bound Alzheimer’s disease drug candidate AZD3293. (GEN News, 09/16/14)

Sanofi and MyoKardia to discover and develop targeted therapies for genetic cardiomyopathies. (GEN News, 09/17/14)

UCSD’s UC-961 for chronic lymphocytic leukemia enters Phase 1 clinical trial; monoclonal antibody that targets protein abnormally used by cancers in their growth. (U-T San Diego, 09/17/14)

UCSD’s startup Diagnologix awarded $25k grant for development of microbubble technology as a platform for isolating rare circulating tumor cells from patient blood samples. (Genome Web, 09/18/14)

Thermo Fisher Scientific completes listing of Ion PGM Dx next-generation sequencing system as a Class II medical device. (Genome Web, 09/18/14)

Boehringer Ingelheim obtains rights to CureVac’s lung cancer mRNA vaccine candidate. (GEN News, 09/18/14)

FDA approves Lilly’s once-weekly injection for patients with type 2 diabetes; improves glycemic control in conjunction with diet and exercise. (Healio, 09/18/14)

Lilly’s Cyramza boosts survival rate in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma. (PharmaTimes Digitial, 09/18/14)

UCSD research shows region of the brain (lateral habenula) is responsible for producing negative emotions akin to disappointment; could lead to better treatment for depression and other mood disorders. (U-T San Diego, 09/19/14)

FDA lifts clinical hold on Halozyme’s study evaluating PEGPH20 in combination with a modified FOLFIRINOX chemotherapy in patients suffering from metastatic pancreatic adenocarcinoma. (Zacks, 09/19/14)

Merck acquires Sigma-Aldrich in $17 billion deal; provides broader product offering in research, pharma, biopharma manufacturing, and diagnostic and testing labs. (Genome Web, 09/22/14)

GlaxoSmithKline and Avalon Ventures launch two new companies with $10 million each in Series A financing and R&D support. (Market Watch, 09/22/14)

AstraZeneca’s MedImmune unit gets fast-track designation for pneumonia treatment. (Pharma Times Digital, 09/23/14)

Celgene’s Otezla approved to treat patients with moderate to severe plaque psoriasis; already approved for treating psoriatic arthritis. (Reuters, 09/23/14)

Scripps Research Institute campuses receive $7.9 million from Defense Advanced Research Projects Agency to create an artificial immune system. (Genome Web, 09/24/14)

BioTheranostics’ Breast Cancer Index test study shows the molecular diagnostic lowers healthcare spending in women with estrogen-receptor positive disease when used at the time of diagnosis or five years after diagnosis. (Genome Web, 09/24/14)

« Return to Table of Contents